Search

Your search keyword '"Leff, J."' showing total 792 results
Start Over Author "Leff, J."
792 results on '"Leff, J."'

1. DEXTENZA versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis

Author

Reich S, Lopez M, Leff J, and Herman J

Subjects
dexamethasone, dextenza, allergic conjunctivitis, Ophthalmology, RE1-994
Abstract

Shani Reich,1 Maria Lopez,2,&ast; Jacqueline Leff,3,&ast; Jordan Herman1 1Clinical Research Center of Florida, Pompano Beach, FL, USA; 2New England Eye Center/Tufts Medical Center, Boston, MA, USA; 3Touro Osteopathic School of Medicine, Touro University, New York, NY, USA&ast;These authors contributed equally to this workCorrespondence: Shani Reich, Tel +1 305 984 7785, Fax + 1 305 570 2642, Email Shani.reich@gmail.comPurpose: To compare clinical outcomes and patient preference for the dexamethasone intracanalicular insert (DEX) versus topical loteprednol (LOT) or olopatadine (OLO) for the treatment of allergic conjunctivitis in a real-world model of allergen exposure.Methods: This was a prospective comparative trial. Adults with testing-confirmed bilateral allergic conjunctivitis received DEX in the more symptomatic eye and either LOT 2 times daily or OLO once daily for 30 days in the fellow eye. The primary outcome was patient preference for treatment. Clinical outcomes included ocular itching and hyperemia, lid swelling, and watering/tearing. Safety outcomes included intraocular pressure (IOP).Results: Thirty patients participated and completed the study. All received DEX in the eye with worse symptoms and 15 received LOT and the other 15 received OLO in the other eye. Patients preferred DEX (10/15; 66.7%) over LOT (4/15; 26.7%), with one patient having no preference (p = 0.0103). Patients had no preference between DEX (8/15; 53.3%) and OLO (6/15; 40%), with one patient having no preference (p = 0.1044). In the DEX/LOT cohort, ocular itching and hyperemia improved more with DEX than LOT (p ≤ 0.009), while in the DEX/OLO cohort, the DEX eyes showed greater improvement in conjunctival hyperemia (p < 0.0001) but not itching (p = 0.074). No between-group differences were seen in eyelid swelling or tearing/watering in either cohort. Mean change in IOP was similar between the DEX and LOT eyes (p = 0.4921), and mean IOP rose more in the DEX eyes than the OLO eyes (by < 1 mmHg; p = 0.0403).Conclusion: Overall, this real-world study demonstrated that the dexamethasone intracanalicular insert was as effective as a topical antihistamine/mast cell stabilizer and more effective than topical steroids in relieving the signs and symptoms of allergic conjunctivitis. This insert should be considered as an alternative to topical therapy for the treatment of allergic conjunctivitis.Keywords: dexamethasone, dextenza, allergic conjunctivitis

Published
2024

12. PDG65 OPIOID USE DISORDER AND HEALTH-RELATED QUALITY OF LIFE

Author

Jalali, A., primary, Ryan, D., additional, Jeng, P., additional, McCollister, K.E., additional, Leff, J., additional, Rotrosen, J., additional, Nunes, E.V., additional, Lee, J.D., additional, Novo, P., additional, Schackman, B.R., additional, and Murphy, S., additional

Published
2020
Full Text
View/download PDF

22. Safety of a Restrictive versus Liberal Approach to Red Blood Cell Transfusion on the Outcome of AKI in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial

Author

Garg A, Badner N, Bagshaw S, Cuerden M, Fergusson D, Gregory A, Hall J, Hare G, Khanykin B, McGuinness S, Parikh C, Roshanov P, Shehata N, Sontrop J, Syed S, Tagarakis G, Thorpe K, Verma S, Wald R, Whitlock R, Mazer C, de Medicis E, Masse M, Marchand J, MacAdams C, Seal D, Ferland A, Ali I, Maier K, Creary T, Tittley L, Spence J, Jaffer I, Brodutch S, Lellouche F, Bussieres J, Dagenais F, Lizotte P, Gagne N, Tremblay H, Breton C, Bouchard P, Bainbridge D, Bentall T, Beique F, Ramachandran S, Rochon A, Vervais M, Grenier S, Grocott H, Kashani H, Ambrose E, McVagh J, Mazer, Hare, Verma, Crescini C, Yagnik S, Slabiak A, Han K, Fremes S, Karkhanis R, Baig N, Sidhu S, MacArthur R, Reid K, Boehnke S, Hudson C, Rubens F, Winch D, Klein R, Grey R, Teoh K, Wiley W, Darby C, Ho A, Saha T, Shore D, Shelley J, Lamarche Y, Sirois C, Brown C, Dube C, Holden K, Roy L, Rolfe B, Brown S, Saczkowski R, Senner W, Carrier F, Noiseux N, Hebert P, Benettaib F, Ghamraoui A, Lebrasseur M, Beattie W, Carroll J, Poonawala H, Zbitnew G, Howells S, Mawhinney R, Sampson S, Yegappan C, Schroeder R, Perfect S, Jones M, Leff J, Nair S, Moncada K, Joco C, Harrison M, Greilich P, Landgraf K, Kramer R, Gallant B, Fontes M, Stavris K, Rosengart T, Debakey M, Omer S, Coffey K, Broussard E, Tseng E, London M, Stanley K, Casson L, Julien M, Myles P, Wallace S, Galagher W, Ditoro A, Royse A, Royse C, Williams Z, Tivendale L, Dong N, Judelman S, Leyden J, Yarad E, Doane M, Player C, Scott D, Slater B, Corcoran P, Hu R, Sidiropoulos S, Baulch S, Brewster D, Simpson S, Smith J, Hulley A, Painter T, de Prinse L, Bannon P, Turner L, Beattie L, Eslick A, Cope L, Sanderson B, Baker R, Pesudovs B, Bennetts J, Dimovski D, Duggan N, Ives K, Yap C, Byrne K, Mans G, Termaat J, Young P, Ridgeon E, Reddy S, Hurford S, Mackle D, Baker T, Hunt A, Cruz R, Henderson S, Mehrtens J, Parke R, Gilder E, Cowdrey K, Dalton J, Butler M, Long S, Lammert A, Blakemore A, Walker C, France D, Hutchison R, Xue S, Gu J, Chen X, Fan A, Suraya S, Raja N, Yusnida I, Azura T, Saibon T, Bing M, Hwang N, Tan R, Ang F, Chin T, Mehta C, Jain A, Sharma P, Shah R, Shaikh P, Kanchi M, Sigamani A, Anusha K, Johansson P, Anderson T, Olesen L, Lilleor N, Rasmussen S, Fenger A, Treskatsch S, Mezger V, Falk E, Habicher M, Sander M, Edinger F, Koch C, Boening A, Oswald I, Bulat-Genc S, Seeberger D, Fassl J, Seeberger E, Eberle B, Takala J, Stucki M, Mateo E, Moreno J, Gabaldon T, Cobo I, Pena J, Ferrer C, Carmona P, Lopez Cantero M, Pajares A, Zarragoikoetxea I, Galan J, Urrutia G, Martinez-Zapata M, Rivilla M, Cegarra V, Acosta-Isaac R, Gajate-Martin L, Candela-Toha A, Simopoulos V, Karangelis D, Filipescu D, Paunescu A, Fawzy H, Mawlana W, Preisman S, Raanani E, Kogan D, Matot I, Cattan A, Artsi H, Galhardo C, Olival S, Toledo R, Villar J, Hernandez E, Montes F, Vaquiro E, Garavito C, Abello M, Manrique E, Vasquez S, Aguilar L, Coral M, Rodriguez H, Tellez J, Martinez C, Biccard B, Alphonsus C, Spiess B, Hall R, Kent B, Denault A, Deschamps A, TRICS Investigators, and Perioperative Anesthesia Clinical

Abstract

Background Safely reducing red blood cell transfusions can prevent transfusion-related adverse effects, conserve the blood supply, and reduce health care costs. Both anemia and red blood cell transfusion are independently associated with AKI, but observational data are insufficient to determine whether a restrictive approach to transfusion can be used without increasing AKI risk. Methods In a prespecified kidney substudy of a randomized noninferiority trial, we compared a restrictive threshold for red blood cell transfusion (transfuse if hemoglobin= 0.3 mg/dl within 48 hours of surgery, or >= 50% within 7 days of surgery. Results Patients in the restrictive-threshold group received significantly fewer transfusions than patients in the liberal-threshold group (1.8 versus 2.9 on average, or 38% fewer transfusions in the restricted threshold group compared with the liberal-threshold group; P

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results